Genmab — April 2017
-
And remember, we don't have to wait years and years for Dara in solid tumors. When the data is as good as JvdW believes, phase 2 studies can be approved and you don't have to wait for the big phase 3 studies
-
JNJ kvartalsregnskab kommer 12:45.
-
Jo 0830 AM - http://www.investor.jnj.com/events.cfm
-
@sowise - det er webcast der starter 14:30.
-
coïncidence?? : Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation
But JNJ has a lot of insight in these markets; if you know a competitor is more successful with a better product, it is wise to pull the plug
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind